Healthcare Industry News: National Comprehensive Cancer Network
News Release - October 22, 2007
JNCCN Named as Reference by CMS for Off-Label Coverage Decisions
JENKINTOWN, Pa.--(HSMN NewsFeed)--JNCCN – The Journal of the National Comprehensive Cancer Network, a peer-reviewed medical journal covering the entire spectrum of oncologic health care, will now be used by the Centers for Medicare & Medicaid Services (CMS) and by its carriers and intermediaries as a mandated reference for off-label use of anti-cancer drugs.Many common cancer treatments are administered off-label, and evidence for such administration is often found in peer-reviewed medical journals. CMS maintains a list of these journals to be used when decisions are made for the Medicare program about such treatments. Last year, CMS conducted a review of its recommended journal resources and determined that the list should be expanded. JNCCN joins that list effective today, October 22, 2007.
JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology™, review articles elaborating on NCCN Guidelines recommendations and health services and clinical research papers discussing new advances and significant controversies and issues. The journal provides the latest information about best clinical practices, oncology outcomes and new research initiatives. More information on JNCCN, including upcoming editorial calendars and subscription information, can be found at www.nccn.org/jnccn.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
The NCCN Member Institutions are: City of Hope, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.
For more information, visit www.nccn.org.
Source: National Comprehensive Cancer Network
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
